Fulcrum therapeutics announces pricing of $125 million public offering of common stock

Cambridge, mass., aug. 11, 2021 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by fulcrum. all of the shares in the offering are being sold by fulcrum. in addition, fulcrum has granted the underwriters a 30-day option to purchase up to 990,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. the offering is expected to close on august 16, 2021, subject to customary closing conditions.
FULC Ratings Summary
FULC Quant Ranking